Literature DB >> 7882347

A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.

K Bhatia1, S Fan, G Spangler, M Weintraub, P M O'Connor, J G Judde, I Magrath.   

Abstract

The growth arrest mediated by p53 is caused at least in part by the p53 mediated expression of p21 (p21waf1/Cip1). Since only one-third of primary Burkitt's lymphomas (BL) demonstrate mutations in the p53 gene, we examined the structural integrity of the p21 coding region by single-strand conformational polymorphism and DNA sequence analysis to determine the extent to which this gene is mutated in BL. Of 34 BLs analyzed, a frequent change (38%) at codon 31 that replaced Ser with Arg was found in 13 samples, 10 of which were from Africa. This change at codon 31 is also detected in peripheral blood DNA from normal subjects and may thus represent a polymorphism. One BL cell line, DH978, carried a change at codon 63: Phe to Leu. This mutation was heterozygous, and both the wild-type and the mutated p21 mRNA were expressed in the tumor cell line. By transfection experiments, the mutant p21 was less efficient in suppressing clonogenicity than wild-type p21. To our knowledge, this is the only mutation described in p21. The availability of this mutant p21 should further help in functional studies of p21.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882347

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Burkitt's lymphoma: new insights into molecular pathogenesis.

Authors:  C Bellan; S Lazzi; G De Falco; A Nyongo; A Giordano; L Leoncini
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

2.  Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.

Authors:  C Cinti; L Leoncini; A Nyongo; F Ferrari; S Lazzi; C Bellan; R Vatti; A Zamparelli; G Cevenini; G M Tosi; P P Claudio; N M Maraldi; P Tosi; A Giordano
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Analysis of the p21 gene in gliomas.

Authors:  Y J Li; K Hoang-Xuan; X P Zhou; M Sanson; K Mokhtari; T Faillot; P Cornu; M Poisson; G Thomas; R Hamelin
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

Review 4.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

5.  Patterns of p21(waf1/cip1) expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas.

Authors:  M J Schwerer; A Sailer; K Kraft; K Baczako; H Maier
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

6.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.

Authors:  L Chin; J Pomerantz; D Polsky; M Jacobson; C Cohen; C Cordon-Cardo; J W Horner; R A DePinho
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

Review 7.  The role of the cell cycle in genitourinary carcinoma.

Authors:  T W McGarvey; S B Malkowicz
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

8.  Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells.

Authors:  Nicole M Jackson; Brian P Ceresa
Journal:  Exp Cell Res       Date:  2016-07-02       Impact factor: 3.905

9.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

10.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

Authors:  L Guedez; W G Stetler-Stevenson; L Wolff; J Wang; P Fukushima; A Mansoor; M Stetler-Stevenson
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.